Progress in targeted therapy for high-risk diffuse large B cell lymphoma / 中国医师杂志

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphoma and is a group of invasive and heterogeneous diseases. Although rituximab in combination with CHOP regimen (R-CHOP) for DLBCL is better, one third of patients have relapsed/refractory conditions. DLBCL is divided into many subtypes due to its high heterogeneity. Different histological types have different response to treatment. High-risk DLBCL has little effect on R-CHOP treatment. How to further improve the first-line cure rate of high-risk DLBCL has become an important challenge in the field of lymphoma treatment. Currently in the era of precision medicine, in recent years, many new targeted drugs, such as immunosuppressive agents, mammalian target of rapamycin (mTOR) receptor inhibitors and Bruton tyrosine kinase (BTK) inhibitors, have been developed for DLBCL-related pathways and molecular targets, provide more new possibilities for the treatment of DLBCL.